Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
CRNX: Notice of proposed and recent insider sales of Common Stock
The filing lists proposed transactions and recent dispositions by an insider. It shows a proposed exercise of stock options to sell 15,000 shares03/18/2026 and proposed settlement of 9,756 Restricted Stock Units03/15/2026. The filing also discloses three 10b5-1 sales of 5,000 shares each01/02/2026, 02/02/2026, and 03/02/2026 with proceeds of $232,590.50, $247,485.50, and $202,234.00, respectively.
Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of Common Stock in open-market transactions. The sales occurred on March 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, meaning the trades were scheduled in advance.
The transactions comprised 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77, within disclosed intraday price ranges. Following these sales, he directly held 16,300 shares of Crinetics Pharmaceuticals common stock.
Crinetics Pharmaceuticals director Stephanie Okey reported an open-market sale of 3,000 shares of common stock at $39.67 per share on March 3, 2026. The trade was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2025, and she now holds 13,300 shares.
Crinetics Pharmaceuticals Chief Financial Officer Tobin Schilke reported an automatic sale of common stock tied to tax withholding. On the transaction date, 6,713 shares of common stock were sold in open-market transactions to cover his tax withholding obligation upon the vesting of restricted stock units granted on March 10, 2025.
The shares were sold pursuant to a pre-arranged Rule 10b5-1 trading plan, with a volume-weighted average price of $39.67 per share and a sale price range of $39.67 to $39.74 per share. After this tax-related sale, he directly held 78,121 shares of Crinetics common stock.
Crinetics Pharmaceuticals reported a change in its independent auditor. The Audit Committee dismissed BDO USA, P.C. as the company’s independent registered public accounting firm and stated that BDO’s reports on the 2024 and 2025 financial statements contained no adverse or qualified opinions.
The company reported no disagreements with BDO and no reportable events during those periods. The Audit Committee appointed PricewaterhouseCoopers LLP (PwC) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026. BDO’s confirming letter to the SEC is filed as an exhibit.